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Abstract
a-synuclein (a-syn) is a synaptic protein in which four mutations (A53T, A30P, E46K and gene triplication) have been found
to cause an autosomal dominant form of Parkinson’s disease (PD). It is also the major component of intraneuronal protein
aggregates, designated as Lewy bodies (LBs), a prominent pathological hallmark of PD. How a-syn contributes to LB
formation and PD is still not well-understood. It has been proposed that aggregation of a-syn contributes to the formation
of LBs, which then leads to neurodegeneration in PD. However, studies have also suggested that aggregates formation is
a protective mechanism against more toxic a-syn oligomers. In this study, we have generated a-syn mutants that have
increased propensity to form aggregates by attaching a CL1 peptide to the C-terminal of a-syn. Data from our cellular study
suggest an inverse correlation between cell viability and the amount of a-syn aggregates formed in the cells. In addition,
our animal model of PD indicates that attachment of CL1 to a-syn enhanced its toxicity to dopaminergic neurons in an age-
dependent manner and induced the formation of Lewy body-like a-syn aggregates in the substantia nigra. These results
provide new insights into how a-syn-induced toxicity is related to its aggregation.
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Introduction
Parkinson’s disease (PD) is a common neurodegenerative
disorder that is marked by the degeneration of dopaminergic
neurons in the substantia nigra pars compacta (SNc) and the
presence of Lewy bodies (LBs) [1–5]. LBs are cytoplasmic
eosinophilic protein aggregates with a-synuclein (a-syn) as one of
the major components [6,7]. a-syn is a synaptic protein in which
four mutations (A53T, A30P, E46K and gene triplication) have
been found to cause an autosomal dominant form of PD [8–13].
The familial PD (FPD) linked point mutations and gene
triplications in a-syn suggest that abnormal structure or excessive
accumulation of a-syn can enhance its toxicity and lead to the
degeneration of dopaminergic neurons in PD. In different studies,
both wild type (WT) and mutant forms of a-syn have been shown
to have a high propensity for forming oligomers and fibrils when
incubated in vitro, while in a-syn transgenic animal model, the
presence of a-syn aggregation is associated with neuronal de-
generation. [4,14–21]. These results suggest that the process of
oligomerization, fibrillization and aggregation of a-syn are the
culprits behind the neurodegeneration seen in PD [13,19,21–24].
However, some studies have also suggested that a-syn aggregates
might be protective and oligomers and pre-fibrilliar a-syn are the
toxic species responsible for neurodegeneration [25]. For instance,
small molecule that facilitates a-syn inclusion formation or histone
deacetylase inhibition that enhances enlarged a-syn inclusion
formation provides protection in cell against a-syn induced toxicity
[26–28]. A recent study has also shown that a-syn mutants that
have reduced propensity to form fibrils and aggregates have
increased toxicity [29]. In this study, we used another approach to
determine if a-syn aggregation is directly related to its cellular
toxicity by generating a-syn mutants that have a higher propensity
to form intracellular aggregates. We used a 16 amino acids peptide
called CL1, which has been shown to destabilize GFP for
proteasomal degradation and enhance the GFP aggregation
[30,31]. We generated a-syn mutants by attaching the CL1
peptide to the C-terminal and studied how the enhancement of a-
syn aggregation affected its toxicity in cellular and animal models.
Our results provide new insights into how a-syn-induced toxicity is
related to its aggregation.
Results
CL1 Sequesters a-syn to the Detergent-insoluble Fraction
of SHSY5Y Cells
To establish a model that could promote the oligomerization
and aggregation of a-syn, we generated wild type (WT) and
mutant a-syn constructs fused with a 16 amino acid peptide
CL1 at the C-terminal and characterized their solubility in the
SHSY5Y cells. WT a-syn (WT), E46K a-syn (E46K), A53T a-
syn (A53T), WT a-syn with CL1 (WT-CL1), E46K a-syn with
CL1 (E46K-CL1) and A53T a-syn with CL1 (A53T-CL1) were
expressed in SHSY5Y cells and their cellular localization was
determined by extraction with soluble and insoluble fractionat-
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enhanced their localization to the insoluble fractions of the cells
(Figure 1A). To rule out the possibility that the accumulation of
WT and mutant a-syn with CL1 in the insoluble fraction was
caused by the extended half-life of a-syn in the cells, we
performed a cycloheximide pulse chase experiment and
monitored the degradation of WT and WT-CL1 a-syn. We
found that both WT and WT-CL1 a-syn levels were
significantly reduced within 24 h (Figure 1 B & C) (F=14.39;
p,0.0001, two way ANOVA). In addition, WT-CL1 a-syn was
degraded significantly faster than WT (Figure 1B & C)
(F=25.93; p,0.0001, two way ANOVA). This result suggested
that increased localization of WT and mutant a-syn with CL1
to the insoluble fraction was not caused by their extended half-
life in the SHSY5Y cells. One of the characteristic of a-syn is
its ability to bind to lipids. To determine if the attachment of
CL1 to a-syn would affect its lipid binding affinity, we used
a lipid sedimentation assay and found that both WT and WT-
CL1 a-syn could bind to liposomes prepared from bovine brain
(Figure 1D), suggesting that CL1 did not alter the lipid-binding
affinity of a-syn.
CL1 Enhances the Oligomerization and Aggregation of a-
syn
We found that CL1 sequesters a-syn to the detergent-insoluble
fraction, therefore, we suspected that CL1 would also enhance a-
syn oligomerization and aggregation. To test this, we expressed
WT and mutant a-syn with and without CL1 in SHSY5Y cells to
determine the presence of a-syn oligomers. As expected, enhanced
formation of SDS-resistant oligomers were observed in both WT
and mutant a-syn with CL1 (Figure 2A). Previous studies have
shown that recombinant a-syn readily forms fibrils and aggregates
after extended incubation at 37uC [22,32,33]. To determine if
CL1 could affect fibrillization of a-syn, we incubated WT and
WT-CL1 a-syn at 37uC for 2 weeks and analyzed the formation of
fibrils by EM. We found that both WT and WT-CL1 a-syn were
able to form fibrils under this condition (Figure 2B). To determine
if CL1 could enhance a-syn aggregation, we incubated recombi-
nant WT and WT-CL1 at 4uC and 37uC for 1 month and
monitored the formation of protein aggregates by AFM. Because
Congo red is known to inhibit a-syn aggregation, we also tested if
CL1-enhanced a-syn aggregation could be inhibited by Congo
red. CL1 significantly enhanced a-syn aggregation and this could
be attenuated by Congo red (Figure 2 C & D). Consistent with
some studies, the a-syn aggregates we observed under AFM were
spherical rather than fibrillar [34,35], as the morphology of a-syn
aggregates examine under AFM is known to be affected by the
physical conditions under which they are formed [36,37]. To
further determine how CL1 could affect a-syn aggregation in
SHSY5Y cells, WT and mutant a-syn with or without CL1
expression in SHSY5Y cells were subjected to immunocytochem-
istry for a-syn. In SHSY5Y cells expressing WT, E46K and A53T
a-syn, diffused cytoplasmic staining was observed (Figure 3A).
However, in SHSY5Y cells expressing WT-CL1, E46K-CL1 and
A53T-CL1 a-syn, large perinuclear a-syn inclusions that resemble
LBs were found (Figure 3A). We also observed similar inclusions in
cortical neurons expressing WT-CL1 a-syn, but not in neurons
expressing WT a-syn (Figure 3B). In addition, we also found that
some of these WT-CL1 inclusions in SHSY5Y cells were positive
for ubiquitin (Ub) or phospho-Ser 129 of a-syn (Figure 3 C & D),
supporting the notion that these a-syn inclusions highly resemble
LBs. Overall, these results showed that CL1 could enhance the
oligomerization and aggregation of a-syn.
CL1 Enhances Aggregation and Cytotoxicity of a-syn
Various studies have shown that a-syn aggregation is linked to
an increased in cytotoxicity, however, the direct correlation
between the level of a-syn aggregation and its induced cytotoxicity
has not been well defined [22,23]. We found that CL1 could
enhance the aggregation of a-syn, therefore, we made use of this
characteristic feature to determine if there was a direct correlation
between a-syn aggregation and cell death. To quantify the level of
a-syn aggregation, we used the filter retardation assay and
measured the amount of trapped a-syn expressing in SHSY5Y
cells. We used the trypan blue exclusion assay to determine the cell
viability simultaneously. To facilitate our analysis, we included
conditions that have been shown to enhance or reduce a-syn-
induced cytotoxicity based on its aggregation. We included cells
that were treated with proteasomal inhibitor (MG132), which
enhanced a-syn aggregation, or cells that were coexpressed with
HSP70, which inhibited a-syn aggregation. Attachment of CL1
significantly enhanced the aggregation of WT and mutant a-syn
(Figure 4 A & B) (F=578.8; p,0.0001, two way ANOVA) and
reduced cell viability (Figure 4C) (F=128.7; p,0.0001, two way
ANOVA). Treatment of MG132 significantly enhanced the
aggregation of WT and mutant a-syn (Figure 4 A & B)
(F=36.75; p,0.0001, two way ANOVA) and reduced cell
viability (Figure 4C) (F=186.1; p,0.0001, two way ANOVA).
Similarly, treatment of MG132 significantly enhanced the
aggregation of WT and mutant a-syn with CL1 (Figure 4 A &
B) (F=203.8; p,0.0001, two way ANOVA) and reduced cell
viability (Figure 4C) (F=160.9; p,0.0001, two way ANOVA).
Coexpression of HSP70 significantly reduced the aggregation of
WT and mutant a-syn (Figure 4 A & B) (F=7.12; p,0.01, two
way ANOVA), but did not change cell viability (Figure 4C)
(F=2.31; p=n.s.; two way ANOVA). Coexpression of HSP70
significantly reduced the aggregation of WT and mutant a-syn
with CL1 (Figure 4 A & B) (F=271.3; p,0.0001, two way
ANOVA), and an increased in cell viability was observed
(Figure 4C) (F=118; p,0.0001, two way ANOVA). To determine
if changes in a-syn induced cytotoxicity in association with
coexpression of HSP70 or treatment of MG132 were not caused
by changes in a-syn expression levels, we also examined the
protein levels of WT and WT-CL1 a-syn. We did not observe any
significant changes in the expression of WT or WT-CL1 a-syn
under different conditions (Figure S1 A & B). These results showed
that enhanced aggregation of a-syn through the attachment of
CL1 or treatment with MG132 was associated with an increased
in a-syn-induced cytotoxicity. In contrast, coexpression of HSP70
reduced aggregation of a-syn and enhanced cell viability. This
relationship between the level of aggregation and a-syn-induced
cytotoxicity was particularly prominent in SHSY5Y cells expres-
sing WT or mutant a-syn with CL1. To further confirm that this
correlation was significant, we performed a correlation analysis for
individual data points and found that there was a significant
inverse correlation between cell viability and the amount of
trapped a-syn (Figure 4D) (Pearson r=20.89, p,0.0001). To
confirm that CL1 enhanced aggregation and increased toxicity of
a-syn was specific to a-syn and not caused by CL1, we generated
b-syn-CL1 and Htt-Q23-CL1 to determine if attachment of CL1
to b-syn and Htt-Q23, which are both non-cytotoxic to SHSY5Y
cells and have similar molecular weight as a-syn, could enhance
their aggregation and affect their cytotoxicity. Attachment of CL1
to b-syn and Htt-Q23 enhanced their aggregation (Figure S1C),
but did not affect their cytotoxicity (Figure S1D), suggesting that
enhanced aggregation and cytotoxicity was specific to a-syn.
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PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38545Figure 1. CL1 sequesters a-syn to the detergent-insoluble fraction of SHSY5Y cells. (A) SHSY5Y cells expressing WT, E46K, A53T, WT-CL1,
E46K-CL1 or A53T-CL1 a-syn were fractionated to soluble and insoluble fractions and analyzed by Western blot. Attachment of CL1 to WT or mutant
a-syn reduced their solubility in the SHSY5Y cells. (B) SHSY5Y cells expressing WT or WT-CL1 a-syn were subjected to cycloheximide pulse chase
analysis. Cells were harvested at different time points and subjected to Western blot analysis. The degradation of WT-CL1 a-syn was enhanced when
compared to WT a-syn. (C) Three independent cycloheximide pulse chase experiments were performed and the levels of WT or WT-CL1 a-syn were
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Cytotoxicity
Although the filter retardation assay can measure the levels of a-
syn aggregation in cells, it does not provide information regarding
the changes in the oligomerization of a-syn. Therefore, we used
the size exclusion chromatography (SEC) to monitor the
oligomerization of WT and WT-CL1 a-syn in SHSY5Y cells.
WT a-syn expression in SHSY5Y cells was mainly eluted at
a major molecular size of approximately 50–60 kDa, which is
consistent with data from several previous studies (Figure 5 A) [38–
41]. WT-CL1 a-syn was eluted at fractions between the molecular
sizes of 200 and 66 kDa (Figure 5A). Interestingly, the attachment
of CL1 to a-syn enhanced its oligomerization as significant higher
molecular weight (HMW) oligomers of WT-CL1 a-syn were
detected (Figure 5 A & B) (F=17.47; p,0.0001, Two way
ANOVA). To confirm that the elution of WT-CL1 a-syn at the
higher molecular weight was not caused by binding to other
cellular proteins, we immunoprecipitated the WT and WT-CL1 a-
syn in SHSY5Y cells and did not observed any major co-
immunoprecipitated proteins (Figure 5C). This supported the
notion that WT-CL1 a-syn had a higher tendency to form HMW
oligomers in SHSY5Y cells. Our cellular data showed that
treatment of MG132 could aggravate the toxicity induced by
WT and WT-CL1 a-syn, which was associated with an increased
in a-syn aggregation (Figure 4). In contrast, coexpression of
HSP70 reduced WT-CL1 a-syn-induced toxicity associated with
reduction in a-syn aggregation (Figure 4). To determine if
oligomerization of WT and WT-CL1 a-syn were also affected in
the treatment of MG132 and coexpression of HSP70, we used
SEC to monitor changes in oligomerization of WT and WT-CL1
a-syn in SHSY5Y cells. MG132 treatment significantly enhanced
WT a-syn oligomerization (Figure 5 A & B) (F=2.15; p,0.05,
Two way ANOVA), but coexpression of HSP70 did not have any
effects on its oligomers formation (Figure 5 A & B) (F=1.19;
p=n.s., Two way ANOVA). For SHSY5Y cells expressing WT-
CL1 a-syn, MG132 treatment significantly enhanced the oligo-
merization of WT-CL1 a-syn (Figure 5 A & B) (F=8.70;
p,0.0001, Two way ANOVA). In contrast, coexpression of
HSP70 significantly reduced the WT-CL1 a-syn oligomerization
(Figure 5 A & B) (F=9.69; p,0.0001, Two way ANOVA).
Overall, these data suggested that conditions that aggravated a-syn
toxicity enhanced its oligomerization, whereas factor that
protected against a-syn cytotoxicity reduced the oligomerization
of a-syn.
CL1 Enhances the Degeneration of Dopaminergic
Neurons by a-syn in an Age-dependent Manner
Our in vitro and cellular results showed that CL1 could enhance
the oligomerization and aggregation of a-syn. To determine if
WT-CL1 a-syn could aggravate a-syn-induced neurodegeneration
in vivo, we generated adenovirus that expressed WT or WT-CL1 a-
syn and infected dopaminergic neurons in mice. First, we
generated the WT and WT-CL1 a-syn expressing adenovirus
and tested their expression efficiency in SHSY5Y cells, and found
that both WT and WT-CL1 a-syn were expressed at a similar level
(Figure 6 A & B). We also tested the infection of tyrosine
hydroxylase (TH) neurons in the substantia nigra pars compacta
(SNc) by stereotactically injecting WT and WT-CL1 a-syn to the
medial forebrain bundle (MFB) and found that these viruses could
effectively infect TH neurons (Figure 6C). To determine if CL1
could aggravate the toxicity towards TH neurons induced by a-
syn, we injected WT and WT-CL1 a-syn expressing adenovirus
stereotactically into mice at the MFB. Then, we monitored the
degeneration of TH neurons by measuring the TH immunoreac-
tivity in the striatum and quantifying TH positive neurons in the
SNc 1, 4 and 6 weeks after injection. Infection of adenovirus
expressing both WT and WT-CL1 a-syn led to the degeneration
of the TH neuronal terminal in the striatum (Figure 7 A, B & E)
(F=14.82; p,0.0001, Two way ANOVA). WT-CL1 a-syn
significantly enhanced the degeneration of TH terminal compared
to WT a-syn in an age-dependent manner (Figure 7 A, B & E)
(F=6.92; p,0.05, Two way ANOVA). Similarly, expression of
both WT and WT-CL1 a-syn led to degeneration of the TH
positive neurons in the SNc (Figure 7 C, D & F) (F=14.87;
p,0.0001, Two way ANOVA). In addition, WT-CL1 a-syn
significantly enhanced the degeneration of TH neurons compared
to WT a-syn in an age-dependent manner (Figure 7 C, D & F)
(F=7.74; p,0.05, Two way ANOVA). Because our in vivo data
showed that WT-CL1 a-syn increased the toxicity of a-syn, we
used the human specific anti-a-syn antibody to determine if a-syn
aggregation was prominent in the SNc. In mice injected with WT
a-syn-expressing adenovirus, we observed a general cytoplasmic
staining in neurons at the SNc (Figure 8 A). In contrast, in mice
injected with WT-CL1 a-syn-expressing adenovirus, in addition to
cytoplasmic staining, perinuclear aggregates that resembled LBs
were observed (Figure 8 B). In summary, these results showed that
WT-CL1 a-syn could enhance the degeneration of dopaminergic
neurons and formation of Lewy body-like aggregates in SNc.
Discussion
Previous studies have suggested that oxidative stress or post-
translational modification such as nitration and phosphorylation
enhance the oligomerization and aggregation of a-syn which can
subsequently cause the degeneration of dopaminergic neurons
[22–24,42–46]. However, the primary toxic species of a-syn has
not been well defined. Initial studies suggested that prominent a-
syn aggregates such as Lewy bodies and neurites are the
components that cause the neuronal degeneration, but studies
have also suggested that protein aggregates might be protective
[22–25]. The understanding of the role of a-syn aggregation in PD
is crucial for the development of novel treatments that target a-syn
aggregation. In this study, we addressed the role of a-syn
aggregation and cytotoxicity by using the characteristic features
of the CL1 peptide. Attachment of CL1 sequestered both WT and
mutant a-syn to the detergent-insoluble fraction of the cells and
facilitated their aggregation. With this approach, we were able to
demonstrate a direct correlation between a-syn aggregation and
reduced cell viability. Interestingly, while WT-CL1 a-syn had
a shorter half-life as determined by the pulse-chase experiment,
the steady state protein level remained comparable to WT a-syn
(Figure 1 A & B). This might suggest that the WT and WT-CL1
expression levels were different and might contribute to the
difference in a-syn aggregation and cell viability. However, we also
found that coexpression of HSP70 or treatment of MG132, which
affected a-syn aggregation and cell viability, did not affect the
overall expression levels of WT and WT-CL1 a-syn (Figure S1 A
quantified using optical densitometry (*p,0.05; **p,0.01). (D) GST, GST-WT a-syn or GST-WT-CL1 a-syn was mixed with or without liposome and
subjected to lipid sedimentation assay. The samples were then analyzed by SDS-PAGE with Coomassie stain. Attachment of CL1 to a-syn did not
affect its lipid binding affinity.
doi:10.1371/journal.pone.0038545.g001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38545Figure 2. CL1 enhances the oligomerization and aggregation of a-syn. (A) SHSY5Y cells expressing WT, E46K, A53T, WT-CL1, E46K-CL1 or
A53T-CL1 a-syn were fractionated to soluble and insoluble fractions and analyzed by Western blot. Attachment of CL1 to WT or mutant a-syn
enhanced the formation of SDS-resistant a-syn oligomers. (B) Recombinant WT or WT-CL1 a-syn were incubated at 37uC for 2 weeks and then
subjected to EM analysis. Both WT and WT-CL1 a-syn were able to form fibrils. (C) Recombinant WT or WT-CL1 a-syn was incubated at 4uCo r3 7 uC
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factor in our study. In addition, the CL1-enhanced aggregation
and increased toxicity of a-syn was specific as attachment of CL1
to b-syn and Htt-Q23 enhanced their aggregation but did not
affect their cytotoxicity. From the SEC, we found that attachment
of CL1 enhanced a-syn oligomerization and this was further
increased in cells treated with MG132. In contrast, coexpression of
HSP70 significantly reduced the oligomerization of a-syn. In-
terestingly, we observed that coexpression of HSP70 could reduce
the size of WT-CL1 as determined by SEC, suggesting that
HSP70 could possibly modulate the overall conformation of WT-
CL1.
Overall, these results suggest that enhanced oligomerization and
aggregation of a-syn is associated with an increased in a-syn
induced-cytotoxicity. From our in vivo animal model of PD, we
found that attachment of CL1 facilitated the formation of Lewy
body-like a-syn aggregates, but at the same time it enhanced the
toxicity induced by a-syn in an age-dependent manner. These
results suggest that enhanced aggregate formation might not be
protective, contrary to some of the suggestions in previous studies
[22–24,26–28]. In this study, we have also established a new
animal PD model by expressing WT-CL1 a-syn in the dopami-
nergic system and caused an age-dependent degeneration of TH
neurons in association with the formation of intraneuronal Lewy
body-like aggregates. This model will be a valuable tool for
studying how a-syn oligomerization and aggregation contribute to
neurodegeneration in PD.
Materials and Methods
Chemicals, Antibodies, Plasmids and Cell Lines
All chemicals were purchased from Sigma (St. Louis, MO)
unless otherwise stated. Antibodies used for immunoblotting
included the following: mouse anti-myc (Roche), mouse anti-HA
(Roche), mouse anti-human a-syn phospho (Ser129) (anti-pS129a-
syn) (Wako Chemicals), mouse anti-a-syn (BD Transduction
Laboratories), mouse anti-human a-syn (LB509; Invitrogen),
mouse anti-b-actin, rabbit anti-tyrosine hydroxylase (anti-TH;
Abcam), rabbit anti-GFP (Abcam), rabbit anti-HA (Sigma) and
rabbit anti-a-syn. pRK5 HA-ubiquitin (HA-Ub), pRK5 WT,
E46K and A53T a-syn were generous gifts from Professor Ted
Dawson (Johns Hopkins University, Baltimore, MD, USA). CL1
(ACKNWFSSLSHFVIHL) [30,31] was fused to the C-terminal of
WT, E46K and A53T a-syn by fusion PCR and cloned into pRK5
vector between the SalI and NotI sites to generate WT-CL1,
E46K-CL1 and A53T-CL1 a-syn. HSPA1A (HSP70) b-synuclein
(b-syn) were PCR from the SuperScript human brain cDNA
library (Invitrogen) and cloned into pRK5-myc by SalI and NotI.
A huntingtin fragment (1–171) with 23 CAG repeats (Htt-Q23)
was a generous gift from Prof. Edwin Chan (CUHK, HKSAR,
China) and was subcloned into pRK5-myc between the SalI and
NotI sites. b-syn-CL1 and Htt-Q23-CL1 were generated by fusion
PCR and cloned into pRK5-myc vector between SalI and NotI.
For recombinant protein production WT and WT-CL1 a-syn
were subcloned into pGEX-4T-2 and pET-28(c) between SalI and
NotI. For the generation of adenovirus, WT and WT-CL1 a-syn
with IRES-EGFP (WT-IRES-EGFP and WT-CL1-IRES-EGFP)
were cloned into the modified pENTR
TM/U6 (Invitrogen) in
which the U6 promoter was replaced by a CMV promoter to
generate pENTR
TM/CMV WT-IRES-EGFP and pENTR
TM/
CMV WT-CL1-IRES-EGFP. The adenovirus expression clones
were then generated by recombination according to the
manufacturer’s instructions. The SHSY5Y cell line was acquired
from ATCC, and the HEK293A cell line was acquired from
Invitrogen.
Recombinant Protein Purification and Antibody
Generation
pGEX-4T-2, pGEX-4T-2-WT a-syn, pGEX-4T-2-WT-CL1 a-
syn, pET-28(c)-WT a-syn and pET-28(c)-WT-CL1 a-syn were
transformed into Rosetta (DE3) pLys E. coli (Novagen) to generate
recombinant protein GST, GST-WT a-syn, GST-WT-CL1 a-syn,
His-WT a-syn and His-WT-CL1 a-syn respectively. Induction was
performed with 0.2 mM IPTG at 16uC for 16–18 h. GST-tagged
recombinant proteins were purified using GSH-Sepharose (GE
Healthcare) and His-tagged proteins were purified using Ni-NTA
Sepharose (GE Healthcare) according to the manufacturer’s
instruction. Purified His-WT a-syn in PBS was mixed with equal
volume of Freund’s adjuvant to form an emulsion. The mixture
was used to immunize a New Zealand white rabbit. Anti-a-syn
antibody was purified from serum with GST-WT a-syn conjugat-
ed to CNBr-activated Sepharose (GE Healthcare) according to
manufacturer’s instruction.
Cell Culture and Transfection
SHSY5Y and HEK293A cells were maintained in Dulbecco’s
Modified Eagle Medium (Invitrogen) supplemented with 10% FBS
(Invitrogen) and antibiotics in a 37uC incubator with 5% CO2.
Transient transfection of DNA to SHSY5Y or HEK 293A cells
was performed using Lipofectamine (Invitrogen) and PLUS
reagents (Invitrogen) according to the manufacturer’s instructions.
Primary cortical neurons from ICR mice were prepared from E16
embryos. Cortical neurons were dissected out and digested with
TrypLE Express (Invitrogen) in Hank’s Balanced Salt Solution
(HBSS) for 15 min. Neurons were then washed twice with HBSS
and resuspended in Neurobasal Medium (NB) supplemented with
2% B-27 and 0.5 mM glutamax with antibiotics (Invitrogen), and
subsequently seeded on poly-L-lysine coated coverslips. Neurons
were transfected with Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s instructions.
Preparation and Analysis of Proteins in the Soluble and
Insoluble Fractions in SHSY5Y Cells
SHSY5Y cells were transfected with plasmids as indicated and
harvested 48 h after transfection by two washes with ice cold PBS.
They were subsequently lysed with Triton soluble buffer (1%
Triton X-100, 0.5 mM EDTA, 1 mM leupeptin, 1 mM aprotinin,
1 mM benzamidine and 10 mM PMSF in TBS) and rotated at
4uC for 1 h. After rotation, cell lysates were centrifuged at
14,000 rpm for 10 min and the supernatant was collected as
Triton soluble fractions. Insoluble fractions were prepared by
resuspending the pellets of the lysate in SDS soluble buffer (1%
Triton X-100, 2% SDS, 1% Na deoxycholate, 1% NP40, 0.5 mM
EDTA, 1 mM leupeptin, 1 mM aprotinin, 1 mM benzamidine
and 10 mM PMSF in TBS) and subjecting them to sonication.
The protein concentration of each sample was determined using
a BCA protein assay kit (Pierce), and samples were then subjected
to Western blot analysis.
with or without Congo red for 1 month and then subjected to AFM analysis. CL1 enhanced the formation of a-syn aggregates and coincubation of
Congo red reduced the size of the aggregates. (D) Quantification of the size of a-syn aggregates in (C) (***p,0.0001).
doi:10.1371/journal.pone.0038545.g002
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38545Figure 3. CL1 induces the formation of Lewy body-like aggregates in SHSY5Y cells and neurons expressing WT or mutant a-syn. (A)
SHSY5Y cells expressing WT, E46K, A53T, WT-CL1, E46K-CL1 or A53T-CL1 a-syn were subjected to immunocytochemistry with anti-a-syn antibody.
Lewy body-like perinuclear aggregates were observed in SHSY5Y cells expressing WT or mutant CL1 a-syn. (B) Primary neurons transfected with WT
or WT-CL1 a-syn were subjected to immunocytochemistry with anti-human a-syn antibody. Prominent a-syn aggregates were observed in cortical
neurons expressing WT-CL1 a-syn. (C) SHSY5Y cells expressing WT-CL1 and HA-Ub were subjected to immunocytochemistry with anti-a-syn and anti-
HA antibodies. Perinuclear inclusion, which was positive for both a-syn and Ub was observed. (D) SHSY5Y cells expressing WT-CL1 were subjected to
immunocytochemistry with anti-a-syn and anti-human a-syn phospho (Ser129) (anti-pS129a-syn). Perinuclear inclusion, which was positive for both
a-syn and pS129a-syn was observed.
doi:10.1371/journal.pone.0038545.g003
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SHSY5Y cells were transfected with plasmids as indicated and
48 h after transfection, cells were treated with 10 mM cyclohex-
imide and harvested at different time point as indicated. Cells were
then lysed with lysis buffer (1% Triton X-100, 2% SDS, 1% Na
deoxycholate, 1% NP40, 0.5 mM EDTA, 1 mM leupeptin, 1 mM
aprotinin, 1 mM benzamidine and 10 mM PMSF in TBS) and
subjected to sonication. The protein concentration of each sample
was determined using the BCA protein assay kit (Pierce), and
subsequently the samples were subjected to Western blot analysis.
The optical density of bands was measured by the gel analysis
function of ImageJ software (National Institute of Mental Health)
normalized to b-actin.
Lipid Sedimentation Assay
The lipid sedimentation assay was performed as described [47]
with small modification. Liposome was prepared by suspending
2 mg/ml of bovine brain lipid extracts (Folch fraction I) in buffer
with 20 mM HEPES (pH 7.4), 150 mM NaCl, and 1 mM DTT.
GST, GST-WT a-syn or GST-WT-CL1 a-syn recombinant
protein (5 mM) was then incubated with 0.5 mg liposome in 100 ml
buffer at 4uC for 2 h and centrifuged at 140,000 g for 15 min. The
supernatant and the pellet were collected and subjected to SDS-
PAGE and stained with Coomassie blue.
Filter Retardation Assay and Cell Death Analysis
SHSY5Y cells were transfected with different plasmids as
indicated and treated with vehicle or MG132 (5 mM) 24 h after
transfection. After 24 h treatment, cells were harvested and half of
the cells were subjected to filter trap retardation assay and the
other half was subjected to the cell viability assay. For the filter
retardation assay, SHSY5Y cells were washed once with PBS,
lysed with lysis buffer (TBS, 2% SDS, 1% NP40, 150 mM NaCl,
10% glycerol, 20 mM NaF, 0.5 mM EDTA, 1 mM leupeptin,
1 mM aprotinin, 1 mM benzamidine and 10 mM PMSF) and
subjected to sonication. The protein concentration of samples was
determined using the BCA Protein Assay Kit (Pierce) and 50 mgo f
protein from each sample was loaded to a 0.2 mm nitrocellulose
membrane (Bio-Rad) in a Bio-Dot Micro-filtration Apparatus
(Bio-Rad), followed by Western blot analysis. For cell viability
analysis, SHSY5Y cells were washed once with PBS, and then
resuspended in FBS containing DMEM. Cell viability was
determined by Trypan blue exclusion assay. The number of live
cells and Trypan blue stained cells were scored and quantified in
a double-blinded manner.
Electron Microscopy (EM)
Purified recombinant His-WT a-syn and His-WT-CL1 a-syn
(3 mM) were incubated at 37uC for 2 weeks with shaking
(250 rpm). After incubation, 10 ml of protein was spotted on the
Formvar-coated, carbon-stabilized copper grid (400 mesh) (SPI
Supplies). The samples were allowed to adsorb for 30 min at
room temperature, washed with 100 ml Millipore-filtered water
and then negatively stained with 1% aqueous uranyl acetate.
Afterwards, the samples were washed with 100 ml Millipore-
filtered water and dried with compressed air. EM images were
obtained with a JEOL 2010 TEM (JEOL Ltd.) at an
accelerating voltage of 120 kV.
Atomic Force Microscope (AFM) Imaging
Purified His-WT a-syn and His-WT-CL1 a-syn at a concen-
tration of 3 mM were incubated for 1 month at 4uCo r3 7 uC
with or without 10 mM Congo red by vigorous shaking
(250 rpm). Before AFM imaging, the protein samples were
gently mixed to resuspend any aggregates and then 5 mlo f
protein was spotted on freshly cleaved mica (Ted Pella). The
samples were allowed to adsorb to the mica for 10 min at room
temperature and then washed with 1 ml Millipore-filtered water
and dried with compressed air. Images were obtained with
a Nanoscope Multimode 8 AFM using the ScanAsyst in air
tapping mode (Veeco/Digital Instruments) with an etched
silicon NanoProbes (model FESP, Digital Instruments). The
raw image data were analyzed using NanoScope Analysis
software (Veeco/Digital Instruments).
Immunocytochemistry of a-syn Aggregation in SHSY5Y
Cells and Neurons
For SHSY5Y cells, 48 h after transfection of plasmids as
indicated, cells were washed once with PBS, then fixed with 4%
ice cold paraformaldehyde (PFA) for 20 min and permeabilized
with 0.2% Triton X-100 for 10 min. Cells were then blocked with
10% normal donkey serum (NDS) for 1 h and subsequently
incubated with mouse anti-a-syn antibody overnight at 4uC. After
overnight incubation, cells were incubated with anti-mouse
secondary antibodies, followed by 49-6-Diamidino-2-phenylindole
(DAPI) for nucleus visualization. For double staining experiment,
SHSY5Y cells transfected with WT-CL1 a-syn and HA-Ub were
sequentially incubated with mouse anti-a-syn and rabbit anti-HA
antibodies. For the staining of phospho-Ser 129 a-syn, SHSY5Y
cells transfected with WT-CL1 a-syn were sequentially incubated
with rabbit anti-a-syn and mouse anti-pS129 a-syn antibodies. For
primary cortical neurons, neurons were transfected with plasmid
as indicated at 3 days in vitro (3DIV). Six days after transfection,
neurons were harvested and stained for human a-syn as described.
All pictures were taken with a confocal microscope (LSM510,
Zeiss).
Size Exclusion Chromatography
SHSY5Y cells transfected with plasmid and treated as indicated
were harvested 48 h after transfection. Cells were then washed
once with PBS and lysed with 0.5% Triton X-100 in TBS at 4uC
for 1 h. After incubation, lysates were centrifuged at 14,000 rpm
for 10 min and filtered with a 0.45 mm filter (Millipore). After
filtration, 3 mg of cell lysate was injected into a superdex 200 (10/
23HR) column (GE healthcare) and the fractions were collected
and subjected to Western blot analysis. The optical density of each
fraction was measured by Image J software (National Institute of
Mental Health) and the elution profiles were presented as the
percentage of the peak elution.
Figure 4. CL1 enhances aggregation and cytotoxicity of a-syn. (A) SHSY5Y cells expressing WT, E46K, A53T, WT-CL1, E46K-CL1 or A53T-CL1 a-
syn under different conditions as indicated were harvested and total cell lysates were prepared and subjected to the filter retardation assay. (B)
Quantification of trapped a-syn aggregates in filter retardation assay by optical densitometry in SHSY5Y cells expressing WT or mutant a-syn with or
without CL1 in different conditions as indicated. (C) Cell viability was determined in the SHSY5Y cells expressing WT, E46K, A53T, WT-CL1, E46K-CL1 or
A53T-CL1 a-syn under different conditions as indicated. (D) The cell viability was plotted against the amount of a-syn trapped for each individual data
point for correlation analysis. There was a significant inverse correlation between cell viability and trapped a-syn (Pearson r=20.89, p,0.0001). These
results were based on three independent experiments.
doi:10.1371/journal.pone.0038545.g004
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SHSY5Y cells transfected with myc-tagged WT or WT-CL1 a-
syn were harvested 48 h after transfection by washing with ice cold
PBS and then lysed with immunoprecipitation (IP) buffer (1%
Triton X-100, 1 mM aprotinin, 1 mM leupeptin, 1 mM benza-
midine, 10 mM PMSF in PBS). The lysates were then rotated at
4uC for 1 h and subsequently centrifuged at 14,000 rpm for
10 min. The supernatant was incubated with 2 mg anti-myc
antibody and protein A agarose (GE Healthcare) at 4uC for 2 h.
After incubation, the agarose was pelleted at 2,000 rpm and
washed 3 times with IP buffer. The precipitates were then
subjected to SDS-PAGE and stained with Coomassie blue.
Adenovirus Production and Viral Analysis
Adenoviral particles were produced by HEK293A cells




TM/CMV WT-CL1-IRES-EGFP, were transfected into
HEK293A cells and grown until cells were detached from the
culture plate. The culture medium and the cells were then
collected and subjected to 3 freeze/thaw cycles between 280uC
Figure 5. Formation of high molecular weight (HMW) a-syn oligomers is linked to increased cytotoxicity. (A) SHSY5Y cells expressing
WT or WT-CL1 a-syn under different conditions as indicated, were harvested and subjected to size exclusion chromatography (SEC) analysis. Fractions
eluted were subjected to Western blot analysis to determine the amount and elution profile of a-syn (B). The elution profile as in (A) for 3
independent experiments were quantified by optical densitometry and presented as the percentage of the peak elution. (C) SHSY5Y cells expressing
WT or WT-CL1 a-syn were subjected to immunoprecipitation and the immunoprecipitates were subjected to SDS-PAGE followed by Coomassie
staining (* and # were the heavy and light chains of antibody).
doi:10.1371/journal.pone.0038545.g005
Figure 6. Establishment of an adenovirus expression system that expresses WT or WT-CL1 a-syn. (A) SHSY5Y cells infected with
adenovirus expressing WT or WT-CL1 a-syn were subjected to Western blot analysis. Similar expression level of WT or WT-CL1 a-syn was observed. (B)
SHSY5Y cells infected with adenovirus expressing WT or WT-CL1 a-syn were subjected to Immunocytochemistry. (C) Dopaminergic neurons of mice in
the SNc were infected with adenovirus expressing WT or WT-CL1 a-syn and subjected to immunohistochemistry. Sections at the SNc were stained
with antibodies against TH and human a-syn.
doi:10.1371/journal.pone.0038545.g006
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PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e38545Figure 7. CL1 enhances the degeneration of dopaminergic neurons by a-syn in an age-dependent manner. Mice were injected with
control or WT a-syn (at the contralateral side) expressing adenovirus in the MFB and were sacrificed 1, 4 and 6 weeks after the injection. The brains
were harvested and the striatum (A) and SNc (C) were subjected to immunohistochemistry with anti-TH antibodies. Mice were injected with control
or WT-CL1 a-syn (at the contralateral side) expressing adenovirus at the MFB and were sacrificed after 1, 4 and 6 weeks of injection. The brains were
harvested and the striatum (B) and SNc (D) were subjected to immunohistochemistry with anti-TH antibodies. (E) The striatal TH terminals injected
Alpha-Syn Oligomerization and Aggregation in PD
PLoS ONE | www.plosone.org 12 June 2012 | Volume 7 | Issue 6 | e38545and 37uC. Samples were centrifuged at 4,000 g for 15 min and
the supernatant containing the adenovirus virus was transferred
to a new tube and stored at 280uC. The infectious unit (IFU)
of the virus was determined by infecting HEK293 cells followed
by FACS analysis as described [48].
Stereotaxic Injection of Adenovirus in Mice
All animals were housed, cared for, and experiments conducted
according to relevant national and international guidelines. The
animal protocols used have been reviewed and approved by the
Animal Ethics Committee of The Hong Kong University of
Science and Technology. Adenovirus with a titer of 2610
9 IFU/
ml (2 ml) was stereotaxically injected into the medial forebrain
bundle (MFB) of C57/BL6 male mice (3 month old) with the
following coordinates; 20.12 mm anterior-posterior, +/
20.12 mm mediolateral, and 20.45 mm dorsoventral. Adenovi-
rus expressing WT-a-syn-IRES-EGFP or WT-a-syn-CL1-IRES-
EGFP was injected on the right side with adenovirus expressing
EGFP as the control injected on the contralateral side.
Immunohistochemistry
Mice were deeply anesthetized with pentobarbital and were
perfused with PBS and 4% PFA in PBS. The mouse brains were
then harvested and post-fixed overnight in 4% PFA and sub-
sequently cryoprotected by incubation in 30% sucrose. Coronal
sections 40 mm in thickness were prepared using a cryostat (Leica).
For fluorescence detection of WT or WT-CL1 a-syn expression in
tyrosine hydroxylase (TH) neurons, sections were incubated with
mouse anti-human a-syn and rabbit anti-TH antibody using the
same procedures as in the immunocytochemistry study. Pictures
were taken with a confocal microscope (LSM510, Zeiss) using a 40
6 Plan Apo Oil NA 1.4 DIC objective (Zeiss). For the
immunostaining using the ABC kit (Vector Laboratories), sections
were first quenched for 10 min in 3% H2O2 and 10% methanol,
then washed with TBS and blocked with 3% normal goat serum.
Sections were then incubated with rabbit anti-TH or mouse anti-
human a-syn antibodies overnight at 4uC. After overnight
incubation, sections were washed and incubated with biotinylated
secondary antibodies (goat anti-rabbit or goat anti-mouse; Vector
Laboratories) for 2 h. After washing, the sections were stained with
the ABC kit according to manufacturer’s instructions. Stained
sections were mounted and dried on gelatinized slides, dehydrated
and coverslipped.
Quantification of TH Terminal Density and Neurons in the
Striatum and SNc
For quantification of TH terminal density and neurons in the
striatum and SNc, mice from 1 week, 4 weeks and 6 weeks time
point (4 mice per time point) were sacrificed and 5 striatal and
SNc sections from each mouse were stained with rabbit anti-TH
antibody using the ABC kit (Vector Laboratories) as described.
Pictures for striatum and SNc were taken using a 2 6 plan apo
objective (Leica). The optical density of the TH terminal was
measured using the ImageJ software (National Institute of
Mental Health). The optical density of the TH terminals was
calculated as the percentage of their contralateral side. The TH
positive neurons in the SNc were quantified in a blind manner
and were calculated as the percentage of their contralateral side.
Data and Statistical Analysis
Data were expressed as SEM, and the student t-test, one way
and two way ANOVA were used to determine statistical
significance.
with WT or WT-CL1 a-syn expressing adenovirus as in (A) and (B) were quantified by optical densitometry. The density of the striatal TH terminals was
presented as percentage intensity of the contralateral side injected with the control adenovirus. Four animals for each time point were measured. (F)
The TH positive neurons in SNc injected with WT or WT-CL1 a-syn expressing adenovirus as in (C) and (D) were quantified in a blind manner. The TH
positive neurons were presented as percentage of the contralateral side injected with the control adenovirus. Four animals for each time point were
measured.
doi:10.1371/journal.pone.0038545.g007
Figure 8. Formation of Lewy body-like aggregates in neurons in the SNc expressing WT-CL1 a-syn. Mice injected with WT (A) or WT-CL1
(B) a-syn expressing adenovirus were sacrificed after 3 months and neurons at the SNc were subjected to immunohistochemistry with the human
specific anti-a-syn antibody LB509. Lewy body-like perinuclear aggregates were observed in the neurons of SNc.
doi:10.1371/journal.pone.0038545.g008
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Figure S1 CL1 enhanced aggregation and increased toxicity in
a-syn is specific. The total protein expression levels of WT (A) and
WT-CL1 (B) a-syn were not affected by coexpression of HSP70 or
treatment with MG132 CL1 also enhanced aggregation in b-syn
and Htt-Q23 (C), but did not affect their toxicity (D).
(TIF)
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